The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s Arexvy vaccine, making it the first approved vaccine for respiratory syncytial virus (RSV) in the world. RSV causes mild symptoms similar to a cold but can be deadly to older adults and infants. The vaccine is approved for use in adults aged 60 years and over and was granted expedited approval in November 2021 amid a surge of patients with RSV, flu, and COVID-19 flooding hospitals. Two other RSV vaccines, one by Pfizer and another by Moderna, are currently under review. The vaccine has also been submitted for approval in Europe.
